EP0159856B1 - Dérivés de 9a-AZA-9a-homoerythromycine dérivés - Google Patents

Dérivés de 9a-AZA-9a-homoerythromycine dérivés Download PDF

Info

Publication number
EP0159856B1
EP0159856B1 EP85302507A EP85302507A EP0159856B1 EP 0159856 B1 EP0159856 B1 EP 0159856B1 EP 85302507 A EP85302507 A EP 85302507A EP 85302507 A EP85302507 A EP 85302507A EP 0159856 B1 EP0159856 B1 EP 0159856B1
Authority
EP
European Patent Office
Prior art keywords
amino
hydrogen
formula
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP85302507A
Other languages
German (de)
English (en)
Other versions
EP0159856A2 (fr
EP0159856A3 (en
Inventor
James Robert Hauske
Arthur Adam Nagel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/600,252 external-priority patent/US4512982A/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to AT85302507T priority Critical patent/ATE37550T1/de
Publication of EP0159856A2 publication Critical patent/EP0159856A2/fr
Publication of EP0159856A3 publication Critical patent/EP0159856A3/en
Application granted granted Critical
Publication of EP0159856B1 publication Critical patent/EP0159856B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Definitions

  • novel antibacterial agents of this invention are derivatives of the well-known macrolide antibiotic, erythromycin A, the compound of the following chemical structure: Even more particularly, the novel antibacterial agents of this invention are derivatives of erthromycin A, in which the 14-membered lactone ring has been expanded to a 15-membered ring by insertion of a nitrogen atom between ring-members 9 and 10, and the 4"-alpha-hydroxy group has been replaced by a substituent bonded to the 4"-position through a nitrogen atom (e.g. a primary amino group).
  • antibacterial agents of this invention can be regarded as derivatives of the compound of the formula II, viz: and for the purposes of this specification, the structure II is named chemically as 9a-aza-9a-homo- erythromycin A, i.e. the locant 9a is used to identify the additional ring member in the lactone ring.
  • 9a-Aza-9a-homoerythromycin A compounds have been disclosed in published British patent application No. 2,094,293 and United States patent No. 4,328,334, where they are named as 11-aza-10- deoxo-10-dihdyroerythromycin A compounds.
  • the coresponding N-methyl derivative is disclosed in EP-A-101186.
  • 4"-Deoxy-4"-amino-erythromycin A and 4"-deoxy-4"-acylamino-erythromycin A antibacterial agents are known from United States patents Nos. 4,150,220 and 2,180,654.
  • This invention provides novel macrolite antibiotics of the formula: and the pharmaceutically-acceptable acid-addition salts thereof; wherein
  • R 2 and R 3 are always hydrogen, but R 2 and R 3 are not both hydrogen;
  • a first preferred group of compounds of this invention consists of the compounds of formula III, wherein R 1 is hydrogen or methyl, and either R 2 is hydrogen and R 3 is amino or R 2 is amino and R 3 is hydrogen.
  • a second preferred group of compounds of this invention consists of the compounds of formula III, wherein R 1 is methyl, R 2 is hydrogen and R 3 is NH ⁇ CO ⁇ R 5 , wherein R 5 is and m and X 1 are as defined previously.
  • a third preferred group of compounds of this invention consists of the compounds of formula III, wherein R 1 is methyl, R 2 is hydrogen and R 3 is NH ⁇ SO 2 ⁇ R 6 , wherein R 6 is and X 3 is as defined previously.
  • Preferred individual compounds of the formula III are:
  • this invention provides novel compounds of the formula: and the acid-addition salts thereof, wherein R 4 is selected from the group consisting of hydrogen, acetyl and propionyl.
  • R 4 is selected from the group consisting of hydrogen, acetyl and propionyl.
  • the compounds of formula IV are useful as intermediates to the antibacterial agents of formula III, wherein R 1 is methyl and R 2 and R 3 are as defined previously.
  • a particularly useful intermediate of the formula IV is 9-deoxo-9a-methyl-4"-deoxy-4"-oxo-9a-aza-9a-homoerythromycin A (the compound of formula IV, wherein R 4 is hydrogen).
  • antibacterial agents of this invention of formula III wherein R 1 is hydrogen or methyl, and either R 2 is hydrogen and R 3 is amino or R 2 is amino and R 3 is hydrogen, can be prepared easily and conveniently from a 4"-deoxy-4"-aminoerythromycin A derivative of the formula V: wherein either R 2 is hydrogen and R 3 is amino or R 2 is amino and R 3 is hydrogen. This is carried out according to Scheme A, in which only partial structures are shown.
  • the 4"-deoxy-4"-amino-erthromycin A compound of formula V is converted into its oxime of formula VI.
  • This is usually carried out by treating the compound of formula V with an excess of hydroxylamine, or an acid-addition salt thereof (e.g. the hydrochloride), in pyridine solution, at a temperature in the range from 20 to 60°C.
  • the reaction usually takes several hours, e.g. about 15 to 50 hours, to reach completion, after which the product is isolated by diluting the reaction mixture with water, and extracting the product into a volatile, water-immiscible, organic solvent, such as ether or ethyl acetate.
  • the product can then be recovered by drying the organic solvent, followed by evaporating the organic solvent in vacuo.
  • the oxime of the formula VI is subjected to a Beckmann rearrangement to give the ring-expanded, 9a-aza-9a-homo-amide of the formula VII.
  • This ring-expansion is conveniently carried out by treating the oxime of formula VI with an excess of 4-toluenesulfonyl chloride in the presence of a base at about room temperature.
  • the oxime is added to aqueous acetone containing sodium bicarbonate, and then the 4-toluenesulfonyl chloride is added with the pH being maintained at about 8 by the addition of sodium hydroxide solution.
  • the rearrangement can be carried out in a water-immiscible organic solvent, such as chloroform, in which case a slight excess of a tertiary amine is added to the oxime and the 4-toluenesulfonyl chloride.
  • a water-immiscible organic solvent such as chloroform
  • the rearrangement proceeds quite rapidly at ambient temperature, and in practice the reaction is allowed to proceed without external cooling. Under these conditions it is normally complete within 1 or 2 hours.
  • aqueous acetone has been used as the reaction solvent, the reaction mixture is diluted with water and the product is extracted into a volatile, water-immiscible organic solvent at a basic pH, followed by solvent evaporation.
  • the product is extracted into an aqueous phase by extraction with water at an acidic pH.
  • the water extract is then basified and the product is extracted into a volatile, water-immiscible organic solvent.
  • the water-immiscible, organic solvent is dried and evaporated in vacuo to give the desired 9a-aza-9a-homo-amide of the formula VII.
  • the compounds of the formula III, wherein R' is hydrogen, and either R 2 is hydrogen and R 3 is amino or R 2 is amino and R 3 is hydrogen, can be obtained by reduction of the 9,9a-amide grouping in the compound of formula VII.
  • This can be carried out using a variety of agents known to reduce amides to amines, but in the present instance a particularly convenient reducing agent is sodium borohydride.
  • sodium borohydride When using sodium borohydride, a solution of the starting amide in a lower-alkanol, e.g methanol, is treated with an excess of solid sodium borohydride, at a temperature from 0° to 30°C., and usually at about room temperature. At room temperature, the reaction proceeds quite smoothly and quickly, and it is normally complete within 1 to 2 hours.
  • the reaction mixture can then be diluted with water and a volatile, water-immiscible, organic solvent, e.g. ethyl acetate.
  • a volatile, water-immiscible, organic solvent e.g. ethyl acetate.
  • the pH is raised to about 10, and the organic layer is removed and dried. Evaporation of the organic layer then affords the desired compound of formula III.
  • the compounds of formula III, wherein R 1 is methyl, and either R 2 is hydrogen and R 3 is amino or R 2 is amino and R 2 is hydrogen, can be prepared by methylation at N-9a of the corresponding compound of formula III, wherein R' is hydrogen.
  • R' is hydrogen
  • the preferred method of converting said compound of formula III, wherein R' is hydrogen, into the corresponding compound of formula III, wherein R' is methyl involves protection of the amino group at C-4", followed by methylation at N-9a, followed by deprotection at C-4".
  • a variety of amino protecting groups can be used to protect the primary amino function at C-4", but particularly convenient groups are the benzyloxycarbonyl group and the 4-nitrobenzyloxycarbonyl group. These groups are attached to C-4" and they are removed from C-4" by standard methods, well-known in the art.
  • said compound of formula III is treated with a slight excess of benzyloxycarbonyl chloride or 4-nitrobenzyloxycarbonyl chloride in the presence of a tertiary amine, such as pyridine or triethylamine, at room temperature, in a reaction-inert organic solvent. The reaction proceeds quite rapidly, and it is usually complete within one hour.
  • the product When a water-immiscible solvent, such as chloroform, has been used, the product is extracted into water at an acidic pH (e.g. pH 2) and then it is back-extracted into a volatile, water-immiscible, organic solvent at a basic pH (e.g. pH 10). Evaporation of the solvent then affords C-4"-protected-amino compound.
  • a water-immiscible solvent has been used, the product can be isolated by diluting the reaction mixture with water and extracting with a volatile, water-immiscible organic solvent at a basic pH (e.g. pH 10). Evaporation of the solvent affords the product.
  • Methylation of the C-4"-protected-amino compound of the formula III, wherein R' is hydrogen can be carried out conveniently using an excess of formaldehyde and formic acid in a reaction-inert organic solvent, such as chloroform.
  • the reaction is usually carried out at a temperature from 60 to 100°C., and it usually takes a few hours, e.g. 2 to 6 hours, to reach completion.
  • the reaction mixture is cooled, and the C-4"-protected-amino compound of formula III, wherein R' is methyl, is isolated in exactly the same manner as described for isolation of the C-4"-protected-amino compound of formula III, wherein R' is hydrogen.
  • the benzyloxycarbonyl or 4-nitrobenzyloxycarbonyl protecting group can be removed from the amino at C-4" by hydrogenolysis in glacial acetic acid solution using palladium-on-carbon catalyst, according to standard procedures.
  • the reaction is usually carried out at room temperature, and at a hydrogen pressure of from 1 to 10 kg/cm 2 .
  • the reaction is normally complete within a few hours, e.g. 4 to 10 hours.
  • the catalyst is then removed by filtration and the acetic acid solution of the product is partitioned between water and a volatile, water-immisicible, organic solvent, such as ethyl acetate, at pH 8 to 10.
  • the organic layer is removed, dried and evaporated to give the desired compound of formula III, wherein R' is methyl.
  • novel 9a-aza-9a-homoerythromycin A derivatives of formula III wherein R 1 is methyl, and either R I is hydrogen and R 3 is amino or R 2 is amino and R 3 is hydrogen, can also be prepared from the known 9a-aza-9a-homoerythromycin A derivative of the formula VIII:
  • the compound of formula VIII is first converted into the corresponding 4"-keto compound of the formula IX: Conversion of the compound of the formula VIII into the compound of the formula IX involves protection of the 2'-hydroxy group, followed by oxidation of the 4"-hydroxy group to a keto group, followed by removal of the protecting group from the 2'-hydroxy group.
  • Protection of the 2'-hydroxy group is usually achieved using a lower-alkanoyl protecting group, e.g. acetyl or propionyl.
  • acetyl or propionyl is attached to the 2'-hydroxy group by treatment of the compound of formula VIII with a slight excess of acetic anhydride or propionic anhydride in chloroform, at room temperature, for several hours, according to standard procedures.
  • Oxidation to the corresponding 2'-O-acetyl-4"-deoxy-4"-keto compound (or its 2'-O-propionyl analog) is then achieved by treatment with dimethyl sulfoxide and a carbodiimide in the presence of a base.
  • N-Ethyl-N'-(N,N-dimethylaminopropyl)-carbodiimide is conveniently used as the carbodiimide and pyridinium trifluoroacetate is conveniently used as the base.
  • removal of the 2'-0-acetyl or 2'-O-propionyl group can be achieved by solvolysis with methanol at 10 to 30°C. for 1 to 2 days, followed by removal of the methanol by evaporation in vacuo.
  • the oxime is prepared by treating the ketone (IX) with an excess of hydroxylamine hydrochloride in methanol solution at room temperature for several hours. It is then isolated by removal of the solvent in vacuo. Reduction of the C-4" oxime of the compound of the formula IX is achieved by treatment with hydrogen, at room temperature, over a Raney nickel catalyst, in a solvent such as a lower-alkanol (e.g. ethanol) and at a pressure in the range form 1 to 10 kg/cm 2 , and preferably 4 to 5 kg/cm 2 . The catalyst is removed by filtration and the product can then be recovered by solvent evaporation.
  • a solvent such as a lower-alkanol (e.g. ethanol)
  • the compound of formula IX can be reductively aminated. This can be achieved by contacting the compound of formula IX with an excess of ammonium acetate, in a loer-alkanol, such as methanol, and then reducing the resulting adduct with sodium cyanoborohydride. In practice this produces the compound of formula III, wherein R' is methyl, R 2 is hydrogen and R 3 is amino, together with its C-4"-epimer. Also, some of the corresponding C-4"-hydroxy compounds (compound VIII and its C-4"-epimer) are formed. The C-4"-hydroxy compounds are readily removed during work-up.
  • the total reaction product is partitioned between ethyl acetate and water at pH 6, under which conditions the C-4"-hydroxy compounds are extracted into the organic layer while the C-4"-amino compounds remain in the aqueous layer.
  • the ethyl acetate layer is separated and discarded, and the pH of the aqueous layer is raised to 9 to 10.
  • the C-4"-amino compounds can then be extracted into an organic phase, which is then separated, dried and evaporated in vacuo.
  • the compound of formula III wherein R 1 is methyl, R 2 is hydrogen and R 3 is amino, can be separated from its C-4"-epimer by chromatography.
  • the antibacterial agents of this invention of the formula III wherein R' is hydrogen or methyl and either R 2 is hydrogen and R 3 is acylated-amino or R 2 is acylated-amino and R 3 is hydrogen, are prepared from the corresponding compound of formula III, wherein R' is hydrogen or methyl, and either R 2 is hydrogen and R 3 is amino or R 2 is amino and R 3 is hydrogen.
  • This latter process involves, therefore, acylation of R 2 or R 3 as amino or R 2 or R 3 as NH-CO-R 5 or NH ⁇ SO 2 ⁇ R 6 , wherein R 5 and R 6 are as defined previously.
  • R 2 or R 3 Acylation of R 2 or R 3 as amino can be carried out using standard techniques.
  • the appropriate compound of formula III, wherein R 2 or R 3 is amino can be acylated by treatment with an activated derivative, such as an acid chloride, of the appropriate acid of the formula R 5 ⁇ CO ⁇ OH or R 6 ⁇ SO 2 ⁇ OH.
  • the reaction is usually carried out by contacting the compound of formula III, wherein R 2 or R 3 is amino, with one molar equivalent or a small excess (i.e. from 1.0 to 1.3 molar equivalents) of the activated derivative of the acid of the formula R 5 ⁇ CO ⁇ OH or R 6 ⁇ SO 2 ⁇ OH in a reaction-insert solvent at a temperature in the range of from 0 to 40°C.
  • Typical solvents which can be used include: chlorinated hydrocarbons, such as dichloromethane and chloroform; low-molecular weight ethers, such as diethyl ether, tetrahydrofuran and dioxane; low-molecular weight ketones, such as acetone and methyl isobutyl ketone; low-molecular weight esters, such as ethyl acetate; and mixtures thereof.
  • chlorinated hydrocarbons such as dichloromethane and chloroform
  • low-molecular weight ethers such as diethyl ether, tetrahydrofuran and dioxane
  • ketones such as acetone and methyl isobutyl ketone
  • low-molecular weight esters such as ethyl acetate
  • an acid chloride it is often convenient to add one molar equivalent of an acid-binder such as triethylamine, pyridine or N,N-dimethylaniline.
  • the reaction proceeds quite rapidly, and it is normally complete within a short time, e.g. 0.5 to 24 hours.
  • the reaction mixture is usually partitioned between a water-immiscible, organic solvent and water, at a pH between 2 and 4.
  • the organic layer is then removed and discarded, and the pH of the aqueous phase is raised to a value from 6.5 to 10, and the product is extracted into a volatile, water-immiscible, organic solvent.
  • the organic solvent is then dried and evaporated to give the acylated product (III; R 2 or R 3 is NH-CO-R 5 or NH ⁇ SO 2 ⁇ R 6 ).
  • the acid formula R 5 ⁇ CO ⁇ OH can be activated by conversion into a mixed anhydride.
  • a carboxylate salt of the acid of formula R 5 ⁇ CO ⁇ OH is reacted with one equivalent of a lower-alkyl chloroformate at a temperature from -40° to 0°C., and preferably about -15°C.
  • Typical carboxylate salts are amine salts such as triethylamine of N-methylmorpholine salts, and the mixed anhydride is usually prepared in the same solvent that is to be used for the acylation reaction, and it is usually used without isolation.
  • the carboxylic acid of the formula R 5 ⁇ CO ⁇ OH can be activated by contacting it with certain agents known in the art form forming peptide bonds.
  • agents include carbodiimides, such as dicyclohexylcarbodiimide, ethoxyacetylene and N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
  • the compounds of formula III, wherein R' is methyl, and either R 2 is hydrogen and R 3 is acylated-amino or R 2 is acylated-amino and R 3 is hydrogen can be prepared by acylation of the corresponding compound of formula III, wherein R 1 is methyl, and either R 2 is hydrogen and R 3 is amino or R 2 is amino and R 3 is hydrogen.
  • the compounds of formula III, wherein R 1 is methyl, and either R 2 is hydrogen and R 3 is acylated-amino or R 2 is acylated-amino and R 3 is hydrogen can also be prepared by methylation of the corresponding compound wherein R' is hydrogen. This methylation is carried out using an excess of formaldehyde and formic acid, in an inert solvent, as described previously for methylation at N-9a.
  • antibacterial agents of this invention of formula III, and the intermediate compounds of formulae IV, V, VI, VII and IX can all be purified after preparation, if desired, by standard procedures for macrolide compounds. Such procedures include recrystallization, column chromatography, preparative thin-layer chromatography and counter-current distribution.
  • the antibacterial compounds of the formula III, and the intermediates of formula IV are basic and therefore they will form acid-addition salts. All such salts are within the scope of this invention, and they can be prepared by standard procedures for macrolide compounds.
  • the compounds of formula III and IV contain more than one basic center, and mono-, di- or tri-acid-addition salts can be prepared.
  • the anionic counter ions can be the same or different.
  • the compound of formula III or IV is combined with a stoichiometric amount of an' appropriate acid in an inert solvent, and then the salt is recovered by solvent evaporation, by filtration if the salt precipitates spontaneously, or by precipitation using a non-solvent followed by filtration.
  • Typical salts which can be prepared include sulfate, hydrochloride, hydrobromide, nitrate, phosphate, citrate, tartrate, pamoate, sulfosalicylate, methanesulfonate, benzenesulfonate and 4-tolunenesulfonate salts.
  • the compound of formula V wherein R 2 is amino and R 3 is hydrogen, can be prepared by hydrogenation of a mixture of the compound of formula X and an excess of ammonium acetate in methanol, at ambient temperature at a hydrogen pressure of ca. 4 kg/cm 2 , using a Raney nickel catalyst. This affords predominantly the C-4"-alpha-amino compound, which can be obtained pure by repeated recrystallization from a solvent such as isopropanol.
  • 9-Deoxo-9a-methyl-9a-aza-9a-homoerythromycin A the compound of formula VIII
  • the antibacterial compounds of formula III and salts thereof exhibit in vitro activity against a variety of Gram-positive microorganisms, e.g., Staphylococcus aureus and Streptococcus pyogenes, and against certain Gram-negative microorganisms such as those of spherical or ellipsodial shape (cocci).
  • Gram-positive microorganisms e.g., Staphylococcus aureus and Streptococcus pyogenes
  • certain Gram-negative microorganisms such as those of spherical or ellipsodial shape (cocci).
  • Their activity is readily demonstrated by in vitro tests against various microorganisms in a brain-heart infusion medium by the usual two-fold serial dilution technique.
  • Their in vitro activity renders them useful for topical application; for sterilization purposes, e.g., sick-room utentils; and as industrial antimicrobials, for example, in water treatment, slim
  • compositions for in vitro use for topical application, it will usually be convenient to prepare pharmaceutical compositions, in which the compound of formula III is combined with a pharmacuetically-acceptable carrier or diluent, for example in the form of ointments and creams.
  • a pharmacuetically-acceptable carrier or diluent for example in the form of ointments and creams.
  • a pharmaceutical composition will normally contain the pharmaceutically-acceptable carrier and the compounds of formula III in a weight ratio in the range from 4:1 to 1:4.
  • antibacterial compounds of formula III are active in vivo versus a variety of Gram-positive microorganisms, e.g. Staphylococcus aureus and Streptococcus pyogenes, and also certain Gram-negative microorganisms, via the oral and parenteral routes of administration, in animals, including man.
  • Their in vivo activity is more limited than their in vitro activity as regards susceptible organisms, and it is determined by the usual procedure which comprises infecting mice of substantially uniform weight with the test organism and subsequently treating them orally or subcutaneously with the test compound.
  • mice In practice, the mice, e.g., 10, are given an intraperitoneal inoculation of suitable diluted cultures containing approximately 1 to 10 times the LD, oo (the lowest concentration of organisms required to produce 100% deaths). Control tests are simultaneously run in which mice receive incoula of lower dilutions as a check on possible variation in virulence of the test organism. The test compound is administered 0.5 hour post-inoculation, and is repeated 4, 24 and 48 hours later. Surviving mice are held for four days after the last treatment and the number of survivors is noted.
  • LD low concentration of organisms required to produce 100% deaths
  • the compounds of formula III and salts thereof can be administered alone, or preferably, in the form of pharmaceutical compositions containing a pharmaceutically-acceptable carrier or diluent.
  • Such compositions can be administered orally, for example as tablets or capsules, or parenterally, which includes subcutaneous and intramuscular injection.
  • the phramaceutically-acceptable carrier will depend on the intended mode of aministration.
  • lactose, sodium citrate and salts of phosphoric acid together with disintegrating agents (such as starch) and lubricating agents (such as magnesium stearate, sodium lauryl sulfate and talc) can be used as the pharmaceutically-acceptable carriers in tablets.
  • disintegrating agents such as starch
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc
  • useful phramaceutically-acceptable carriers are lactose and high molecular weight polyethylene glycols (e.g., having molecular weight from 2,000 to 4,000).
  • sterile solutions or suspensions can be prepared, wherein the pharmaceutically-acceptable carrier is aqueous (e.g.
  • isotonic saline or isotonic dextrose or non-aqueous (e.g., fatty oils of vegetable origin such as cottonseed or peanut oil, or polyols such as glycerol or propylene glycol).
  • non-aqueous e.g., fatty oils of vegetable origin such as cottonseed or peanut oil, or polyols such as glycerol or propylene glycol.
  • a pharmaceutical composition will usually contain the pharmaceutically-acceptable carrier and the compound of formula III or salt thereof in a weight ratio in the range of 4:1 to 1:4.
  • the usual daily dosage of an antibacterial compound of the formula III, or a salt thereof will be in the range offrom 5 to 100 mg/kg of body weight, especially 10 to 50 mg/kg of body weight, in single or divided doses.
  • Part B (0.40 g) was dissolved in 5 ml of glacial acetic acid, and then 100 mg of 10% palladium-on-carbon was added, under nitrogen. The resulting mixture was shaken under an atmosphere of hydrogen for 5.5 hours at a pressure of ca. 4 kg/cm 2 , and then the catalyst was removed by filtration. To the filtrate was added ethyl acetate and water and the pH of the aqueous phase was adjusted to 9.5. The ethyl acetate layer was removed, and the aqueous layer was extracted with further ethyl acetate. The ethyl acetate solutions were combined, washed with water and dried. Evaporation of the dried solution gave 0.04 g of 9-deoxy-9a-methyl-4"-deoxy-4"-beta-amino-9a-aza-9a-homoerythromycin A.
  • the title compound can be prepared form 9-deoxo-4"-deoxy-4"-alpha-amino-9a-aza-9a-homo- erythromycin A by reaction with benzyloxycarbonyl chloride, followed by reaction with formaldehyde- formic acid, followed by hydrogenolysis, using the procedures of Parts A, B and C of Example 1.
  • the pH of the aqueous layer was adjusted to 5 and the dichloromethane layer was removed.
  • the aqueous residue was then extracted with dichloromethane at pH 6.0, 6.5 and 10.
  • the dichloromethane splution from the extraction at pH 10 was evaporated in vacuo and the residue recrystallized from ether, to give a first crop of the desired 9a-aza-9a-homo compound.
  • the dichloromethane solution from the extraction at pH 6.5 was evaporated in vacuo to give a second crop of the desired 9a-aza-9a-homo compound.
  • the mother liquor from the ether recrystallization was evaporated in vacuo to give a crop of the desired 9a-aza-9a-homo compound.
  • the three crops were combined to give 1.0 g of the desired 9a-aza-9a-homo compound.
  • a mixture was prepared from 14.0 g (18.7 mmole) of 4"-deoxy-4"-beta-aminoerythromycin A from Part A, 5.3 g (28 mmole) of 4-toluenesulfonyl chloride, 4.2 ml (30 mmole) of triethylamine and 100 ml of chloroform, with stirring. The temperature rose to 33°C., and then the reaction mixture was cooled to room temperature with ice-bath cooling. The reaction mixture was stirred at room temperature for 1 hour, and then an excess of water was added. The pH of the aqueous phase was adjusted to 5 using 1 N hydrochloric acid and the layers were separated.
  • the 4"-deoxy-4"-beta-amino-9a-aza-9a-homoerythromycin A from Step B (7.0 g; 9.4 mmole) was dissolved in 300 ml of methanol and cooled to 10-15°C. in an ice-bath. To this solution was then added 7.5 g (0.2 mole) of sodium borohydride portionwise with stirring, during about 20 minutes. Stirring was continued for 3 hours and then an excess of water was added. The resulting mixture was extracted several times with cholorform and the extracts were drived and evaporated in vacuo.
  • the resulting aqueous phase from the ethyl acetate extraction was further extracted with chloroform, and the chloroform solution was dried and evaporated to give 4.5 g of residue.
  • the residue was dissolved in 300 ml of chloroform, and 150 g of silica gel was added. The mixture was stirred at room temperature for 18 hours, and then it was filtered. The silica gel was washed with 300 ml of chloroform, followed by 500 ml of chloroform/methanol/ammonium hydroxide (110:1:0.1), followed by 500 ml of chloroform/methanol/ ammonium hydroxide (4:1:0.1).
  • the aqueous layer was removed and the pH was adjusted to 6.2.
  • the aqueous layer was extracted at pH 6.5 to remove the 4"-hydroxy products and the extracts were discarded.
  • the pH of the aqueous layer was then raised to 9.5 and the aqueous layer was then further extracted with chloroform.
  • the latter extracts were dried and evaporated in vacuo.
  • the residue was redissolved in water at pH 2.
  • the aqueous solution thus obtained was extracted with chloroform at pH 2, pH 6.2 and pH 9.5.
  • the chloroform solution from the extraction at pH 9.5 was dried, evaporated and again dissolved in water at pH 2. This latter aqueous solution was extracted with chloroform at pH 2, pH 6.2 and pH 9.5.
  • a solution was prepared from 1.0 g (1.3 mmole) of 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A, and 0.13 ml (1.4 mmole) of acetic anhydride in 15 ml of chloroform was stirred for several hours at room temperature. To the solution was added an excess of water and stirring was continued for 30 minutes with the pH being held at 9. The organic phase was then removed, dried and evaporated to give 1.0 g of the desired 2'-O-acetyl compound.
  • a mixture was prepared from 7.5 g (9.5 mmole) of 9-deoxy-9a-methyl-2'-O-acetyl-9a-aza-9a-homo- erythromycin A, 5.5. g (28 mmole) of N-ethyl-N'-(N,N-dimethylaminopropyl)carbodiimide and 6.7 ml (95 mmole) of dimethyl sulfoxide in 75 ml of dichloromethane. To this mixture was then added, dropwise, with stirring, during 3 minutes, 5.5 g (28 mmole) of pyridinium trifluoroacetate. The temperature rose to 39°C. and then returned to room temperature.
  • the title compound can be prepared by repeating Example 7, but replacing the acetic anhydride used in Part A by an equimolar amount of propionic anhydride.
  • the title compound was prepared in 40% yield by reaction of 9-deoxo-4"-deoxy-4"-beta-amino-9a-aza-9a-homoerythromycin A with the mixed anhydride prepared from 2-(4-aminophenyl)acetic acid and isobutyl chloroformate, using the procedure of Example 14.
  • the concentrated filtrate was then poured with stirring into a mixture of 250 ml of water and 200 ml of chloroform, and the pH of the aqueous layer was adjusted to 5.4.
  • the organic layer was removed and discarded and the aqueous layer was further extracted with chloroform at pH 5.4.
  • the further extracts were discarded.
  • the pH of the aqueous phase was adjusted to 9.6 and then the aqueous phase was extracted with chloroform.
  • the latter extracts were dried (Na 2 S0 4 ) and then concentrated in vacuo to give 5.74 g of a white foam.
  • the foam was dissolved in 35 ml of hot isopropanol, and the solution was allowed to cool to room temperature with stirring.
  • the solid which had formed was recovered by filtration and dried, to afford 3.54 g of 4"-deoxy-4"-alpha-amino- erythromycin A, contaminated with 5-10% of its 4"-epimer.
  • the proportion of 4"-beta-amino epimer can be reduced by successive recrystallizations from isopropanol.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (12)

1. Procédé de préparation d'un composé antibiotique macrolide de formule
Figure imgb0063
ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce composé; formule dans laquelle
R1 est l'hydrogène ou le groupe méthyle; et
R2 et R3 représentent chacun l'hydrogène, un groupe amino, un groupe NH-CO-R5 ou un groupe NH-SO2-R6;
sous réserve que l'un de R2 et R3 soit toujours l'hydrogène mais que R2 et R3 ne soient pas tous deux de l'hydrogène;
ou:
(i) R5 est choisi dans le groupe des restes Alk, -(CH2)n-Ar1 ,
Figure imgb0064
Figure imgb0065
dans lesquels Alk est un reste alkyle ayant 1 à 8 atomes de carbone; Ar1 est un radical thiényle, furyle, isoxazolyle, pyridyle, pyrazinyle ou pyrimidyle; X' est l'hydrogène, un radical fluoro, chloro, bromo, hydroxy, amino, nitro, trifluorométhyle, alkyle ayant 1 à 3 atomes de carbone ou alkoxy ayant 1 à 3 atomes de carbone; X2 est l'hydrogène, un radical fluoro, chloro ou bromo; n a la valeur 0 ou 1; et m a la valeur 0,1, 2 ou 3; et
(ii) R6 est choisi dans le groupe constitué des restes Ar2 and
Figure imgb0066
où Ar2 est un reste thiényle ou furyle et X3 est l'hydrogène ou un radical chloro, bromo ou iodo; caractérisé en ce que
(A) un composé de formule
Figure imgb0067
est réduit avec un réactif capable de réduire un amide en une amine, pour former un composé de formule
Figure imgb0068
après quoi, le cas échéant, on effectue l'une des transformations suivantes ou les deux:
(i) fixation d'un groupe protecteur à celui de R2 et R3 qui est un groupe amino, méthylation en N-9a en utilisant un excès de formaldéhyde et d'acide formique et élimination du groupe protecteur de R2 ou R3; et
(ii) acylation de celui de R2 et R3 qui est un groupe amino avec un dérivé activé d'un acide de formule R5-CO-OH ou R6-SO2-0H;
ou (B), pour les composés de formule III dans laquelle R1 est un groupe méthyle, R2 est un groupe amino, NH-CO-R5 ou NH-SO2-R6, et R3 est l'hydrogène, réaction d'un composé de formule
Figure imgb0069
avec un excès de chlorhydrate d'hydroxylamine, suivie d'une réduction à l'hydrogène gazeux sur un catalyseur au nickel de Raney; suivie elle-même, le cas échéant, d'une acylation avec un dérivé activé d'un acide de formule R5-CO-OH ou R6SO2-OH:
ou (C) pour les composés de formule III dans laquelle R' est un groupe méthyle, R2 est l'hydrogène et R3 est un groupe amino, NH-CO-R5 ou NH-SO2-R6, réaction d'un composé de formule
Figure imgb0070
avec un excès d'acétate d'ammonium et de cyanoborohydrure de sodium;
suivie, le cas échéant, d'une acylation avec un dérivé activé d'un acide de formule R5-CO-OH ou R6-SO2-OH.
2. Procédé suivant la revendication 1, dans lequel R2 et R3 sont chacun un atome d'hydrogène ou un groupe amino.
3. Procédé suivant la revendication 1 (A), dans lequel R2 et R3 représentent chacun l'hydrogène ou un groupe amino, caractérisé en ce que le réactif capable de réduire un amide en amine est le borohydrure de sodium.
4. Procédé suivant la revendication 3, dans lequel R' est l'hydrogène et la réduction au borohydrure de sodium est effectuée dans un solvant qui est un alcanol inférieur, à une température de 0° à 30°C.
5. Procédé suivant la revendication 3, dans lequel R' est un groupe méthyle, et la réduction au borohydrure de sodium est effectuée dans un solvant qui est un alcanol inférieur, à une température de 0° à 30°C;
la réduction étant suivie de la fixation du groupe benzyloxycarbonyle ou 4-nitrobenzyloxycarbonyle protecteur à celui de R2 et R3 qui est un groupe amino, d'une méthylation en N-9a et de l'èlimination du groupe protecteur par hydrogénolyse.
6. Procédé suivant la revendication 1 (B), dans lequel R2 est un groupe amino, caractérisé en ce que la réaction avec le chlorhydrate d'hydroxylamine est conduite en solution méthanolique à la température ambiante et est suivie d'un traitement à l'hydrogène, à la température ambiante, sur un catalyseur au nickel de Raney, dans un solvant qui est un alcanol inférieur, à une pression comprise dans l'intervalle de 1 à 10 kg/cm2.
7. Procédé suivant la revendication 1 (C), dans lequel R3 est un groupe amino, caractérisé en ce que la réaction avec un excès d'acétate d'ammonium et de cyanoborohydrure de sodium est conduite dans un solvant qui est un alcanol inférieur, à la température ambiante.
8. Procédé de préparation d'une composition pharmaceutique, caractérisé par la mélange d'un composé de formule (III) tel que défini dans la revendication 1 ou d'un sel d'addition d'acide pharmaceutiquement acceptable de ce composé avec un diluant ou support pharmaceutique.
9. Composé de formule (III) suivant la revendication 1, ou un sel d'addition d'acides pharmaceutiquement acceptable de ce composé.
10. Composé de formule (IV) suivant la revendication 1.
EP85302507A 1984-04-13 1985-04-10 Dérivés de 9a-AZA-9a-homoerythromycine dérivés Expired EP0159856B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT85302507T ATE37550T1 (de) 1984-04-13 1985-04-10 9a-aza-9a-homoerythromycin-derivate.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/600,252 US4512982A (en) 1984-04-13 1984-04-13 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
US600252 1984-04-13
US06/616,529 US4518590A (en) 1984-04-13 1984-06-04 9α-Aza-9α-homoerythromycin compounds, pharmaceutical compositions and therapeutic method
US616529 1984-06-04

Publications (3)

Publication Number Publication Date
EP0159856A2 EP0159856A2 (fr) 1985-10-30
EP0159856A3 EP0159856A3 (en) 1986-03-19
EP0159856B1 true EP0159856B1 (fr) 1988-09-28

Family

ID=27083554

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85302507A Expired EP0159856B1 (fr) 1984-04-13 1985-04-10 Dérivés de 9a-AZA-9a-homoerythromycine dérivés

Country Status (19)

Country Link
US (1) US4518590A (fr)
EP (1) EP0159856B1 (fr)
KR (1) KR860002111B1 (fr)
AU (1) AU549235B2 (fr)
CA (1) CA1234805A (fr)
DE (1) DE3565267D1 (fr)
DK (1) DK164785A (fr)
EG (1) EG17459A (fr)
ES (3) ES8607335A1 (fr)
FI (1) FI851449L (fr)
GR (1) GR850900B (fr)
HU (1) HU195668B (fr)
IE (1) IE57739B1 (fr)
IL (1) IL74865A (fr)
NO (1) NO161497C (fr)
NZ (1) NZ211769A (fr)
PH (1) PH21185A (fr)
PT (1) PT80270B (fr)
YU (3) YU62385A (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075289A (en) * 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
US4904644A (en) * 1988-08-03 1990-02-27 Schering Corporation Antimicrobial compound isolated from Actinomadura fulva subsp indica
US5912331A (en) * 1991-03-15 1999-06-15 Merck & Co., Inc. Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A
DE69227713D1 (de) 1991-03-15 1999-01-14 Merck & Co Inc 9-Deoxo-9(Z)-hydroxyiminoerythromycin A und O-Derivate hiervon
US5985844A (en) * 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
EP0579770B1 (fr) * 1991-04-09 1996-06-26 Abbott Laboratories Agents procinetiques a base de lactame macrocyclique
US5189159A (en) * 1992-04-02 1993-02-23 Merck & Co., Inc. 8a-AZA-8a-homoerythromycin cyclic iminoethers
US5523399A (en) * 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives
US5215980A (en) * 1992-01-17 1993-06-01 Merck & Co., Inc. 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof
US5210235A (en) * 1992-08-26 1993-05-11 Merck & Co., Inc. Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics
US5332807A (en) * 1993-04-14 1994-07-26 Merck & Co., Inc. Process of producing 8A- and 9A-azalide antibiotics
WO1994026758A1 (fr) * 1993-05-19 1994-11-24 Pfizer Inc. Intermediaire s'appliquant a l'azithromycine
US5441939A (en) * 1994-03-04 1995-08-15 Pfizer Inc. 3"-desmethoxy derivatives of erythromycin and azithromycin
FR2739620B1 (fr) * 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
USRE38426E1 (en) * 1995-10-09 2004-02-10 Aventis Pharma S.A. 5-O-deosaminyl 6-O-methyl erythronolide A derivatives, preparation method therefor and use thereof for preparing biologically active materials
AU2001280000A1 (en) 2000-08-23 2002-03-04 Jaweed Mukarram, Siddiqui Mohammed Process for preparation of anhydrous azithromycin
MXPA03009786A (es) 2001-04-27 2004-01-29 Pfizer Prod Inc Procedimiento para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-sustituidos.
WO2003070174A2 (fr) 2002-02-15 2003-08-28 Sympore Gmbh Conjugues de composes biologiquement actifs, procedes de preparation et d'utilisation, et formulation et applications pharmaceutiques
CA2476448A1 (fr) 2002-02-15 2003-08-28 Sympore Gmbh Conjugues antibiotiques
WO2003070173A2 (fr) 2002-02-15 2003-08-28 Sympore Gmbh Conjugues de composes biologiquement actifs, methodes de preparation et d'utilisation des conjugues, formulation et applications pharmaceutiques obtenues a partir desdits conjugues
GB0310992D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101186A1 (fr) * 1982-07-19 1984-02-22 Pfizer Inc. N-méthyl-11-aza-10-déoxy-10-dihydro-érythromycine A, produits intermédiaires et leurs procédés de préparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150220A (en) * 1977-02-04 1979-04-17 Pfizer Inc. Semi-synthetic 4"-erythromycin A derivatives
SE445223B (sv) * 1977-02-04 1986-06-09 Pfizer Sett att framstella 4"-amino-erytomylin-a-derivat
US4180654A (en) * 1978-01-03 1979-12-25 Pfizer Inc. 4"-Deoxy-4"-acylamido derivatives of oleandomycin, erythromycin and erythromycin carbonate
SI7910768A8 (en) * 1979-04-02 1996-06-30 Pliva Pharm & Chem Works Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4465674A (en) * 1983-09-06 1984-08-14 Pfizer Inc. Azahomoerythromycin D derivative and intermediates therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101186A1 (fr) * 1982-07-19 1984-02-22 Pfizer Inc. N-méthyl-11-aza-10-déoxy-10-dihydro-érythromycine A, produits intermédiaires et leurs procédés de préparation

Also Published As

Publication number Publication date
HU195668B (en) 1988-06-28
EP0159856A2 (fr) 1985-10-30
NO851466L (no) 1985-10-14
EP0159856A3 (en) 1986-03-19
ES8704965A1 (es) 1987-04-16
AU4107085A (en) 1985-10-17
NZ211769A (en) 1987-10-30
ES542134A0 (es) 1986-06-16
KR860002111B1 (ko) 1986-11-26
PT80270B (pt) 1987-10-20
DE3565267D1 (en) 1988-11-03
FI851449L (fi) 1985-10-14
YU62385A (en) 1988-02-29
NO161497C (no) 1989-08-23
NO161497B (no) 1989-05-16
ES8607335A1 (es) 1986-06-16
ES8705458A1 (es) 1987-05-01
FI851449A0 (fi) 1985-04-11
PT80270A (en) 1985-05-01
IE850912L (en) 1985-10-13
PH21185A (en) 1987-08-12
ES551503A0 (es) 1987-04-16
DK164785A (da) 1985-12-10
KR850007435A (ko) 1985-12-04
HUT37629A (en) 1986-01-23
CA1234805A (fr) 1988-04-05
YU126887A (en) 1988-02-29
AU549235B2 (en) 1986-01-23
IL74865A0 (en) 1985-07-31
GR850900B (fr) 1985-11-25
DK164785D0 (da) 1985-04-12
YU126787A (en) 1988-02-29
IE57739B1 (en) 1993-03-24
EG17459A (en) 1992-12-30
US4518590A (en) 1985-05-21
IL74865A (en) 1987-12-31
ES551502A0 (es) 1987-05-01

Similar Documents

Publication Publication Date Title
EP0159856B1 (fr) Dérivés de 9a-AZA-9a-homoerythromycine dérivés
US4512982A (en) 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method
EP0649430B1 (fr) Derives de macrolides antibiotiques a noyau a 16 elements
SK5812001A3 (en) Novel macrolide antibiotics
US4440759A (en) 20-Amino tylosin derivatives and pharmaceutical compositions containing same
US4150220A (en) Semi-synthetic 4"-erythromycin A derivatives
JPH0140039B2 (fr)
EP0124216A1 (fr) Dérivés de macrolides modifiés en C-20 et C-23
US6140479A (en) Erythromycin a derivatives
US20030203858A1 (en) 5-O-mycaminosyltylonide derivatives
US4468511A (en) C-20- And C-23-Modified macrolide derivatives
EP0262904A2 (fr) Modifications de la mycinose et de la 3-0-déméthylmycinose dans des macrolides du type tylosine
SI9520124A (sl) Derivati eritromicin A 9-0-oksima, obdarjeni z antibiotično aktivnostjo
EP0000656B1 (fr) Dérivés du 4"-uréido-oléandomycine, procédé pour leur préparation et leur emploi dans des compositions pharmaceutiques
JPS5827799B2 (ja) ４″−アミノ−オレアンドマイシン誘導体
HU182559B (en) Process for producing 4-two comma above-deoxy-4-two comma above-amino-erythromycin a derivatives of antibacterial activity
CA1236830A (fr) Derives de macrolide avec modifications en c-20 et c-23
US4124755A (en) 11-Alkanoyl-4"-deoxy-4"-isonitrilo-oleandomycin derivatives
FI68404B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 4"deoxi-4"-aminoerytromycin-a-derivat
SE445922B (sv) 4"-deoxi-4"-arylglyoxamido- och -aroyltioformamido-derivat av oleandomycin och av dess estrar
KR820000742B1 (ko) 올레안도 마이신의 4"-데옥시-4"-아릴글리옥사미도 및 아로일티오포름아미도 유도체와 그의 에스테르의 제법
IE47968B1 (en) Oleandomycin-derived carbamates and thiocarbamates
WO2000006586A1 (fr) Derive d'erythromycine ayant une activite antibiotique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19850419

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19870625

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 37550

Country of ref document: AT

Date of ref document: 19881015

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3565267

Country of ref document: DE

Date of ref document: 19881103

ITF It: translation for a ep patent filed

Owner name: MODIANO & ASSOCIATI S.R.L.

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 85302507.0

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20030313

Year of fee payment: 19

Ref country code: AT

Payment date: 20030313

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20030318

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20030331

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20030403

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20030407

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20030430

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20030514

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20030605

Year of fee payment: 19

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040410

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040410

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

BERE Be: lapsed

Owner name: *PFIZER INC.

Effective date: 20040430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041103

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20040410

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041231

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20041101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST